Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: Prognostic correlations

Journal of Surgical Oncology

Volumn 104, Issue 6, 2011, Pages 701-705

  Rena, Ottavio ^a   Boldorini, Luciano R ^a   Gaudino, Erica ^a   Casadio, Caterina ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; EPIDERMAL GROWTH FACTOR RECEPTOR;

AGE; AGED; ARTICLE; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENDER; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT PLEURA MESOTHELIOMA; OVERALL SURVIVAL; PHENOTYPE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME;

AGED; FEMALE; FOLLOW-UP STUDIES; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MESOTHELIOMA; MUTATION; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 80053584652     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21901     Document Type: Article

References (22)

1. Yang H, Testa JR, Carbone M,: Mesothelioma epidemiology, carcinogenesis and pathogenesis. Curr Treat Options Oncol 2008; 9: 147-157.
2. Trousse DS, Avaro JP, D'Journo XB, et al.: Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies. Eur J Cardiothorac Surg 2009; 36: 759-763.
3. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al.: Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21: 3798-3807. (Pubitemid 46606235)
4. Martin V, Mazzucchelli L, Frattini M,: An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology. J Clin Pathol 2009; 62: 314-324.
5. Yarden Y,: The EGFR family and its ligands in human cancer. Signalling mechanism and therapeutic opportunities. Eur J Cancer 2001; 37: S3-S8. (Pubitemid 32938123)
6. Arteaga CL,: The epidermal growth factor receptor: From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001; 19: S32-S39.
7. Slichenmyer WJ, Fry DW,: Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin Oncol 2001; 28: 67-79. (Pubitemid 33065112)
8. Cai Y, Roggli V, Mark E, et al.: Transforming growth factor alpha and epidermal growth factor receptor in reactive and malignant mesothelioma proliferations. Arch Pathol Lab Med 2004; 128: 68-70. (Pubitemid 38049570)
9. Dazzi H, Hasleton P, Thatcher N, et al.: Malignant pleural mesothelioma and epidermal growth factor receptor (EGFR). Relationship of EGFR with histology and survival using fixed paraffin-embedded tissue and the F4, monoclonal antibody. Br J Cancer 1990; 61: 924-926. (Pubitemid 20197007)
10. Ramael M, Segers K, Buysse C, et al.: Immunohistochemical distribution patterns of epidermal growth factor receptor in malignant mesothelioma and non-neopalstic mesothelium. Virchows Arch A Pathol Anat Histopathol 1991; 419: 171-175.
11. Govindan R, Kratzke RA, Herdon II JE, et al.: On behalf of the cancer and leukemia group B. Gefitinib in patients with malignant mesothelioma: A phase II study by Cancer and Leucemia Group. Clin Cancer Res 2005; 11: 2300-2304. (Pubitemid 40490190)
12. Trupiano J, Geisinger K, Willingham M, et al.: Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol 2004; 17: 476-481. (Pubitemid 41646604)
13. Destro A, Ceresoli GL, Falleni M, et al.: EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 2006; 51: 207-215. (Pubitemid 43144364)
14. Garland L, Rankin C, Scott K, et al.: Molecular correlates of the EGFR signalling pathway in association with SWOG S0218: A phase II study of oral EGFR tyrosine kinase inhibitor OSI- 774 (NSC-718781) in patients with malignant pleural mesothelioma (MPM). Proc ASCO 2004; 22: 3007.
15. Edwards JG, Swinson DEB, Jones JL, et al.: EGFR expression: Associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 2006; 54: 399-3407.
16. Okuda K, Sasaki H, Kawano O, et al.: Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma. J Cancer Res Clin Oncol 2008; 134: 1105-1111.
17. Nicholson RI, Gee JMW, Harper ME,: EGFR and cancer prognosis. Eur J Cancer 2001; 37: S9-S15. (Pubitemid 32938124)
18. Gaafar R, Bahnassy A, Abdelsalam I, et al.: Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma. Lung Cancer 2010; 70: 43-50.
19. O'Byrne KJ, Edwards JG, Walzer DA,: Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma. Lung Cancer 2004; 45S: S45-S48. (Pubitemid 38917113)
20. Cappuzzo A, Hirsh FR, Rossi E, et al.: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 2005; 97: 643-655. (Pubitemid 40812628)
21. Mendelsohn J, Baselga J,: The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19: 6550-6565. (Pubitemid 32197693)
22. Huang SM, Harari PM,: Epidermal growth factor receptor inhibition in cancer therapy: Biology, rationale and preliminary clinical Results:. Invest New Drugs 1999; 17: 259-269. (Pubitemid 30037958)